Method for reducing pericardial fibrosis and adhesion formation

US6211217A · kind A · utility

Assignee

• Novartis AG · CH

Inventors

• Francis G. Spinale · Charleston, US
• Marc De Gasparo · Rossemaison, CH

Key dates

• Filing date: Mar 16, 1999
• Grant date: Apr 3, 2001
• Expiry date: Mar 16, 2019

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/41
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT.sub.1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)bip henyl-4-yl-methyl]amine (valsartan) of formula ##STR1## or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.